Show simple item record

dc.creatorIvanović, Darko
dc.creatorMalenović, Anđelija
dc.creatorJančić, Biljana
dc.creatorMedenica, Mirjana
dc.creatorMasković, Marija
dc.date.accessioned2019-09-02T11:10:00Z
dc.date.available2019-09-02T11:10:00Z
dc.date.issued2007
dc.identifier.issn1082-6076
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/941
dc.description.abstractThe multi-component preparation Co -Diovan (R) is indicated for the hypertension treatment in patients whose blood pressure is not adequately controlled by monotherapy. Its active ingredients are valsartan and hydrochlorothiazide. The reversed-phase high performance liquid chromatographic method (RP -HPLC) for the determination of valsartan and hydrochlorothiazide, as well as their impurities level, was developed and described in this paper. As the investigated substances were structurally different with extremely different lipophilicity and polarity, isocratic elution was not possible, so an optimal gradient mode was settled on. The chromatograms were recorded using the Agilent 1100 Series chromatographic system with DAD detector. Separations were performed on a Hypersil 120-5 ODS column (250 mm x 4.6 mm; 5 mm particle size) at 25 degrees C column temperature. The gradient high performance liquid chromatographic system was developed, and the following mobile phases were used: A) mixture acetonitrile -water (10: 90 V/V); pH of the mobile phase was adjusted to 2.5 with 85% orthophosphoric acid, and B) mixture acetonitrile -water (90: 10 V/V); pH of the mobile phase was adjusted to 2.5 with 85% orthophosphoric acid. Injection volume was 50 mu L, flow rate 1 mL min(-1) and UV detection was performed at 256 nm. Methyl parahydroxybenzoate was used as an internal standard and acetonitrile-water (40:60 V/V) as a solvent. Afterwards, the developed method was subjected to the method validation. The investigated validation parameters (selectivity, linearity, precision, accuracy, LOQ, and LOD) proved the suitability of the method for the simultaneous determination of valsartan, hydrochlorothiazide, and their impurities in appropriate tablets.en
dc.publisherTaylor & Francis Inc, Philadelphia
dc.relationinfo:eu-repo/grantAgreement/MESTD/MPN2006-2010/142077/RS//
dc.rightsrestrictedAccess
dc.sourceJournal of Liquid Chromatography & Related Technologies
dc.subjecthigh performance liquid chromatographyen
dc.subjectvalidationen
dc.subjectvalsartanen
dc.subjecthydrochlorothiazideen
dc.subjectimpuritiesen
dc.titleMonitoring of impurity level of valsartan and hydrochlorothiazide employing an RP-HPLC gradient modeen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractМаленовић, Aнђелија; Масковић, Марија; Меденица, Мирјана; Ивановић, Дарко; Јанчић, Биљана;
dc.citation.volume30
dc.citation.issue19
dc.citation.spage2879
dc.citation.epage2890
dc.citation.other30(19): 2879-2890
dc.citation.rankM23
dc.identifier.wos000250551600006
dc.identifier.doi10.1080/10826070701588638
dc.identifier.scopus2-s2.0-34548306907
dc.identifier.rcubconv_1923
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record